MD Anderson Cancer Center
1515 Holcombe Boulevard
200 articles with MD Anderson Cancer Center
This week will have moderate activity by the U.S. Food and Drug Administration (FDA). Although they jumped the gun on Regeneron and Sanofi’s cancer drug, there are still plenty of other decisions being made this week. Here’s a look.
10/19/2018TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.
Berkeley Lights calls itself a digital cell biology company. It develops and markets tech platforms for what it calls “the intersection of biology, technology and information.”
Cyclacel Pharmaceuticals and MD Anderson Cancer Center Announce Strategic Alliance to Study Novel Cyclacel Medicines in Hematological MalignanciesMulti-product agreement builds on long-term clinical collaboration in hematological malignancies
Cyclacel Pharmaceuticals, Inc. and The University of Texas MD Anderson Cancer Center today announced a three-year strategic alliance agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines.
Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer.
Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round.
First In Class Immunostimulating Anticancer Agent able to Directly Inhibit Tumor Signaling and Kill Tumor Cells, is in Clinical Trial for Glioblastoma and Melanoma Metastatic to the Brain
In the ongoing challenge to combat the almost always deadly brain cancers, namely Glioblastoma and melanoma metastasized to the brain, the pharmaceutical company Moleculin Biotech, Inc., (Nasdaq: MBRX) has initiated a Phase 1 clinical trial of a new first-in-class cancer drug candidate.
The death of Sen. John McCain helped raise awareness about the plight of brain tumor patients and the lack of movement on developing new therapies for this disease over the past several years. But now, Houston-based Moleculin Biotech has launched a clinical trial that could be a game-changer if a...
Genprex Amends Options to License Additional Cancer Fighting Technologies from the University of Texas MD Anderson Cancer Center
Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements between Genprex and MD Anderson
The University of Texas MD Anderson Cancer Center today was awarded $30 million to support research, core facilities, recruitment and prevention efforts from the Cancer Prevention and Research Institute of Texas (CPRIT).
According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7.3 percent of cancer deaths.
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
Immatics Initiates Second Phase I Clinical Trial of its Unique ACTengine® Platform in Patients with Advanced Solid Cancers
Immatics, a leading company in the field of cancer immunotherapy, today announced that it has initiated enrollment of patients into a phase I trial of IMA202, its second T-cell receptor (TCR)-transduced adoptive cell therapy program.
Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating therapies for multiple hematologic malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes.
Genprex Updates Agreement with University of Texas MD Anderson Cancer Center to Resume Patient Enrollment in Phase I/II Study Evaluating Oncoprex/Erlotinib Combination Therapy in Non-Small Cell Lung Cancer
Genprex, Inc. announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational drug Oncoprex™ and erlotinib (Tarceva®)
Oncoceutics, Inc. announced the publication of a scientific research article in the journal Clinical Cancer Research that demonstrates utility for the company’s imipridone portfolio of compounds in neuro-oncology.
Genprex Enters Agreement with the University of Texas MD Anderson Cancer Center to Study Oncoprex in Combination with Immunotherapies
New study will evaluate synergistic effect of Oncoprex gene therapy on checkpoint inhibition
Phase III study shows quizartinib prolongs overall survival for patients with deadly type of relapsed or refractory AML
A study led by The University of Texas MD Anderson Cancer Center revealed that the investigational drug quizartinib prolonged overall survival for patients with a deadly form of acute myeloid leukemia (AML).
Seattle Genetics Announces First Patient Dosed in Phase 2 Trial of Tisotumab Vedotin for Women with Recurrent or Metastatic Cervical Cancer
Seattle Genetics, Inc. (Nasdaq:SGEN) today announced dosing of the first patient in the phase 2 innovaTV 204 clinical trial.
Amgen, and The University of Texas MD Anderson Cancer Center, announced two multi-year collaborative research deals for a broad range of cancer therapeutics.